What protein is most commonly associated with sensorineural hearing loss in children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Connexin 26 (Encoded by GJB2 Gene)

Connexin 26, a gap junction protein encoded by the GJB2 gene, is the protein most commonly responsible for sensorineural hearing loss in children, accounting for 50% of all autosomal recessive nonsyndromic hearing loss and 15-40% of all deaf individuals in various populations. 1

Molecular Basis and Mechanism

  • Connexin 26 is a gap junction protein of the beta subunit class that functions in cell-to-cell diffusion and recycling of small molecules such as potassium in the inner ear. 1

  • The GJB2 gene, along with the closely related GJB6 gene (encoding connexin 30), comprises the DFNB1 locus, which represents the single most important genetic cause of childhood deafness. 1

  • More than 150 different deafness-causing variants have been identified in GJB2, though a few common mutations account for the majority of cases in most populations. 1

Clinical Characteristics

  • GJB2-related hearing loss is typically sensorineural, bilateral, present at birth, and nonprogressive, ranging from mild to profound severity. 1

  • High-frequency hearing loss (4000-8000 Hz) is a characteristic audiometric feature in children with molecularly confirmed connexin 26 mutations. 2

  • Progressive or later-onset hearing loss can occur, particularly with truncating variants. 1

Diagnostic Approach

For children with nonsyndromic sensorineural hearing loss, GJB2 mutation screening by sequence analysis should be performed as the first-line genetic test, as it can avoid expensive and potentially invasive diagnostic procedures when positive. 1

Testing Algorithm:

  • Simplex cases (isolated cases): Perform CMV testing first, then proceed to GJB2 sequencing. 1

  • Multiplex cases (affected first-degree relatives): Proceed directly to connexin 26 testing without delay. 1

  • Both parents deaf: Connexin-related deafness is strongly suspected, as the vast majority of marriages between deaf individuals producing deaf offspring involve GJB2 mutations. 1

Population-Specific Considerations

  • The most common pathogenic mutations vary by ethnicity, with 35delG being prevalent in Caucasian populations and other mutations predominant in Asian and other ethnic groups. 1

  • In the German population, GJB2 mutations account for 22% of severe to profound hearing loss cases. 3

  • Among Indian populations, insertions at nucleotides 30-35 (40% of cases) and deletions at nucleotide 59 (20% of cases) are the most common pathogenic mutations. 4

Critical Clinical Pitfall

A negative GJB2 mutation screen does NOT exclude genetic etiology—this distinction is frequently misunderstood and inadequately conveyed to families. 1 The probability of genetic causation remains substantial even with negative testing, varying based on family history and number of hearing siblings. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Detection of Connexion 26 GENE (GJB2) Mutations in Cases of Congenital Non Syndromic Deafness.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.